US 11,919,953 B2
TIGIT and CD112R blockade
Sue J. Sohn, Daly City, CA (US); Marissa Mock, Newbury Park, CA (US); Ian Nevin Foltz, Burnaby (CA); Agnieszka Kielczewska, Vancouver (CA); Kathy Manchulenko, Port Coquitlam (CA); Yannick Bulliard, Thousand Oaks, CA (US); and Xiaoshan Min, Burlingame, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Jul. 14, 2021, as Appl. No. 17/375,958.
Claims priority of provisional application 63/212,315, filed on Jun. 18, 2021.
Claims priority of provisional application 63/052,011, filed on Jul. 15, 2020.
Prior Publication US 2022/0017616 A1, Jan. 20, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 41 Claims
 
1. A CD112R antigen-binding protein comprising a heavy chain (HC) complementarity-determining region (CDR) 1, HC CDR2, HC CDR3, light chain (LC) CDR1, LC CDR2, and LC CDR3 comprising the amino acid sequences selected from the group consisting of: (a) SEQ ID NOs: 13-18, respectively; (b) SEQ ID NOs: respectively; (c) SEQ ID NOs: 33-38, respectively; (d) SEQ ID NOs: 43-48, respectively; (e) SEQ ID NOs: 53-58, respectively; (f) SEQ ID NOs: 63-68, respectively; (g) SEQ ID NOs: 73-78, respectively; (h) SEQ ID NOs: 83-88, respectively; (i) SEQ ID NOs: 93-98, respectively; (j) SEQ ID NOs: 103-108, respectively; (k) SEQ ID NOs: 233-238, respectively; (l) SEQ ID NOs: 1973-1978, respectively; (m) SEQ ID NOs: 1983-1988, respectively; (n) SEQ ID NOs: 1993-1998, respectively; and (o) SEQ ID NOs: 2003-2008, respectively.